Clinical trial perspective for adult and juvenile Huntington′s disease using genetically-engineered mesenchymal stem cells

Progress to date from our group and others indicate that using genetically-engineered mesenchymal stem cells (MSC) to secrete brain-derived neurotrophic factor (BDNF) supports our plan to submit an Investigational New Drug application to the Food and Drug Administration for the future planned Phase...

Full description

Bibliographic Details
Main Authors: Peter Deng, Audrey Torrest, Kari Pollock, Heather Dahlenburg, Geralyn Annett, Jan A Nolta, Kyle D Fink
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2016-01-01
Series:Neural Regeneration Research
Subjects:
Online Access:http://www.nrronline.org/article.asp?issn=1673-5374;year=2016;volume=11;issue=5;spage=702;epage=705;aulast=Deng

Similar Items